FDA Grants Orphan Drug Status For Can-Fite’s Liver Cancer Drug

Can-Fite BioPharma obtained US Food and Drug Administration (FDA) Orphan Drug Status for CF102 – a drug for primary liver cancer (hepatocellular carcinoma.) The drug was found to be safe in preclinical and Phase I clinical trials. Orphan Drug Status is granted for drugs being developed for the treatment of diseases that affect a small number of people. The status provides incentives and preferences for the research, production and marketing of these drugs, including seven years marketing exclusivity from the date of approval, tax breaks, and exemptions on FDA fees. View and share